22 December 2025
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announces that, on 18 December 2025, it was notified of a transaction in the Company's ordinary shares of $0.25 each (Ordinary Shares), by Nazneen Rahman, Non-Executive Director, on 18 December 2025, as set out below.
|
PDMR |
Position |
Nature of the transaction |
Quantity |
Price per Ordinary Share |
|
Nazneen Rahman |
Non-Executive Director |
Sale of Ordinary Shares |
297 |
£134.96 |
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Nazneen Rahman |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Non-Executive Director |
||||
|
b) |
Initial notification/Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
AstraZeneca PLC |
||||
|
b) |
LEI |
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4i |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 |
||||
|
b) |
Nature of the transaction |
Sale of Ordinary Shares of US$0.25 each in AstraZeneca PLC |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information - Aggregated volume - Price |
Not applicable - single transaction |
||||
|
e) |
Date of the transaction |
18 December 2025 |
||||
|
f) |
Place of the transaction |
LON |
||||
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit www.astrazeneca.com and follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC